newsfilter
← Latest News
Business Wire·

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

Additional preliminary data from ongoing LEGEND study of detalimogene in pivotal cohort of BCG-unresponsive NMIBC with CIS anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains